Immunex gains on psoriasis data

IMNX was up $0.64 to $16.86 on Tuesday. After market close on Monday, IMNX announced that its Enbrel etanercept soluble TNF inhibitor met the primary endpoint of the proportion of patients experiencing a 75% improvement in Psoriasis Area and Severity Index (PASI 75) after 12 weeks compared to placebo in a Phase II study (see BioCentury Extra, Monday Aug. 20). ...